Business Context and Reporting Period
Company: Viridian Therapeutics, Inc. (VRDN)
Filing Type: Form 8-K (Current Report)
Date: September 10, 2024
Subject: Announcement of topline data from the Phase 3 THRIVE trial for veligrotug (VRDN-001) in active thyroid eye disease (TED) and updates on the clinical pipeline.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document. Investors should refer to the most recent Form 10-Q for financial data.
Material Changes and Clinical Results
The primary material event is the successful completion of the Phase 3 THRIVE trial for veligrotug in active TED. The trial met its primary and all secondary endpoints at 15 weeks with high statistical significance (p < 0.0001).
- Proptosis: 70% responder rate for veligrotug vs. 5% for placebo (64% placebo-adjusted). Mean reduction was 2.9 mm vs. 0.5 mm.
- Diplopia: 54% complete resolution for veligrotug vs. 12% for placebo. 63% achieved a diplopia response vs. 20% for placebo.
- Clinical Activity Score (CAS): 64% of patients achieved a CAS of 0 or 1 vs. 18% for placebo. Mean reduction was 3.4 points vs. 1.7 points.
- Overall Response: 67% of veligrotug patients achieved an overall response vs. 5% for placebo.
- Safety: Veligrotug was generally well-tolerated with a 4% discontinuation rate and no treatment-related serious adverse events. Hearing impairment occurred in 16% of the treatment arm vs. 10.5% in placebo (5.5% placebo-adjusted).
Guidance, Outlook, and Management Commentary
Management views the THRIVE data as strong support for a potential best-in-class profile for veligrotug and its successor, VRDN-003.
- Veligrotug (VRDN-001): The company anticipates submitting a Biologics License Application (BLA) in the second half of 2025.
- THRIVE-2: Enrollment for the Phase 3 trial in chronic TED was completed in July 2024, with topline data expected by year-end 2024.
- VRDN-003: Two global Phase 3 trials (REVEAL-1 and REVEAL-2) for a subcutaneous version of the drug were initiated in August 2024. Topline data is anticipated in the first half of 2026, with a BLA submission targeted for year-end 2026.
Risks: The filing includes standard forward-looking statement disclaimers regarding clinical trial timelines, regulatory approvals, manufacturing risks, and the sufficiency of cash to fund operations.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical tables and safety data not fully summarized in the 8-K.
- Review the most recent Form 10-Q (filed August 8, 2024) to assess current cash runway and liquidity given the upcoming BLA submission timeline.
- Monitor the "Risk Factors" section of the 10-Q for specific details on regulatory hurdles and competition in the TED treatment market.
- Confirm the enrollment status and protocol details for the REVEAL-1 and REVEAL-2 trials for VRDN-003.